Progress towards understanding the pathogenesis of dengue hemorrhagic fever

Dengue AntigensJawahar Raina
0 comments

Products Related to West Nile, Dengue, Malaria, T.B, Chikungunya, Sars, Zika

Product# 30070: Recombinant Dengue D2 Envelope Protein (E.coli)    

Product# 30170: Recombinant Dengue Antigen D2 Envelope Protein (Baculo) 

Product# 30030: Recombinant Dengue D3 NS1 (E.coli)

 

 

Abstract

Dengue virus (DENV) is a mosquito-borne virus belonging to the Flaviviridae family. There are 4 serotypes of DENV that cause human disease through transmission by mosquito vectors. DENV infection results in a broad spectrum of clinical symptoms, ranging from mild fever to dengue hemorrhagic fever (DHF), the latter of which can progress to dengue shock syndrome (DSS) and death. Researchers have made unremitting efforts over the last half-century to understand DHF pathogenesis. DHF is probably caused by multiple factors, such as virus-specific antibodies, viral antigens and host immune responses. This review summarizes the current progress of studies on DHF pathogenesis, which may provide important information for achieving effective control of dengue in the future.

 

 

Keywords: DENV, dengue hemorrhagic fever (DHF), NS1, genome, antibody-dependent enhancement (ADE), T cell

Footnotes

This article is published with open access at Springerlink.com

ORCID: 0000-0001-7447-5488

Compliance with Ethics Guidelines

The authors declare that they have no conflict of interests. This article does not contain any studies with human or animal subjects performed by any of the authors.

Go to:

References

  1. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, Gonzalez D, Castro O, Kouri G, Halstead SB, Guzman MG. Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg. 2006;75:1113–1117. [PubMed] [Google Scholar]
  2. Anderson JR, Rico-Hesse R. Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Am J Trop Med Hyg. 2006;75:886–892. [PMC free article] [PubMed] [Google Scholar]
  3. Avirutnan P, Zhang L, Punyadee N, Manuyakorn A, Puttikhunt C, Kasinrerk W, Malasit P, Atkinson JP, Diamond MS. Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog. 2007;3:e183. [PMC free article] [PubMed] [Google Scholar]
  4. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. 2015;7:304. [PubMed] [Google Scholar]
  5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013;496:504–507. [PMC free article] [PubMed] [Google Scholar]
  6. Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis. 2008;8:86. [PMC free article] [PubMed] [Google Scholar]
  7. Brown MG, Hermann LL, Issekutz AC, Marshall JS, Rowter D, Al-Afif A, Anderson R. Dengue virus infection of mast cells triggers endothelial cell activation. J Virol. 2011;85:1145–1150. [PMC free article] [PubMed] [Google Scholar]
  8. Chaichana P, Okabayashi T, Puiprom O, Sasayama M, Sasaki T, Yamashita A, Ramasoota P, Kurosu T, Ikuta K. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One. 2014;9:e92173. [PMC free article] [PubMed] [Google Scholar]
  9. Chan-Hui PY, Swiderek KM. Immunological considerations for developing antibody therapeutics for Influenza A. Hum Vaccin Immunother. 2016;12:474–477. [PMC free article] [PubMed] [Google Scholar]
  10. Chang RY, Hsu TW, Chen YL, Liu SF, Tsai YJ, Lin YT, Chen YS, Fan YH. Japanese encephalitis virus non-coding RNA inhibits activation of interferon by blocking nuclear translocation of interferon regulatory factor 3. Vet Microbiol. 2013;166:11–21. [PubMed] [Google Scholar]
  11. Chapman EG, Costantino DA, Rabe JL, Moon SL, Wilusz J, Nix JC, Kieft JS. The structural basis of pathogenic subgenomic flavivirus RNA (sfRNA) production. Science. 2014;344:307–310. [PMC free article] [PubMed] [Google Scholar]
  12. Chen HL, Lin SR, Liu HF, King CC, Hsieh SC, Wang WK. Evolution of dengue virus type 2 during two consecutive outbreaks with an increase in severity in southern Taiwan in 2001–2002. Am J Trop Med Hyg. 2008;79:495–505. [PubMed] [Google Scholar]
  13. Chen HR, Chuang YC, Lin YS, Liu HS, Liu CC, Perng GC, Yeh TM. Dengue Virus Nonstructural Protein 1 Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy. PLoS Negl Trop Dis. 2016;10:e0004828. [PMC free article] [PubMed] [Google Scholar]
  14. Chuang YC, Lin J, Lin YS, Wang S, Yeh TM. Dengue Virus Nonstructural Protein 1-Induced Antibodies Cross-React with Human Plasminogen and Enhance Its Activation. J Immunol. 2016;196:1218–1226. [PubMed] [Google Scholar]
  15. Chuang YC, Wang SY, Lin YS, Chen HR, Yeh TM. Reevaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection. J Biomed Sci. 2013;20:42. [PMC free article] [PubMed] [Google Scholar]
  16. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745–748. [PMC free article] [PubMed] [Google Scholar]
  17. Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol. 1997;142:897–916. [PubMed] [Google Scholar]
  18. Funk A, Truong K, Nagasaki T, Torres S, Floden N, Balmori Melian E, Edmonds J, Dong H, Shi PY, Khromykh AA. RNA structures required for production of subgenomic flavivirus RNA. J Virol. 2010;84:11407–11417. [PMC free article] [PubMed] [Google Scholar]
  19. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007;104:9422–9427. [PMC free article] [PubMed] [Google Scholar]
  20. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, Kurane I, Rothman AL, Ennis FA. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis. 1999;180:1429–1435. [PubMed] [Google Scholar]
  21. Gubler DJ. Emerging vector-borne flavivirus diseases: are vaccines the solution. Expert Rev Vaccines. 2011;10:563–565. [PubMed] [Google Scholar]
  22. Gubler DJ, Suharyono W, Lubis I, Eram S, Gunarso S. Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg. 1981;30:1094–1099. [PubMed] [Google Scholar]
  23. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013;158:1445–1459. [PubMed] [Google Scholar]
  24. Guzman MG, Kouri G, Halstead SB. Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics. Lancet. 2000;355:1902–1903. [PubMed] [Google Scholar]
  25. Halstead SB. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970;42:350–362. [PMC free article] [PubMed] [Google Scholar]
  26. Halstead SB. Immune enhancement of viral infection. Prog Allergy. 1982;31:301–364. [PubMed] [Google Scholar]
  27. Halstead SB, Cohen SN. Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiol Mol Biol Rev. 2015;79:281–291. [PMC free article] [PubMed] [Google Scholar]
  28. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis. 2002;8:1474–1479. [PMC free article] [PubMed] [Google Scholar]
  29. Hermann LL, Gupta SB, Manoff SB, Kalayanarooj S, Gibbons RV, Coller BA. Advances in the understanding, management, and prevention of dengue. J Clin Virol. 2015;64:153–159. [PubMed] [Google Scholar]
  30. Hladish TJ, Pearson CA, Chao DL, Rojas DP, Recchia GL, Gomez-Dantes H, Halloran ME, Pulliam JR, Longini IM. Projected Impact of Dengue Vaccination in Yucatan, Mexico. PLoS Negl Trop Dis. 2016;10:e0004661. [PMC free article] [PubMed] [Google Scholar]
  31. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB J. 2000;14:1603–1610. [PubMed] [Google Scholar]
  32. Jaiyen Y, Masrinoul P, Kalayanarooj S, Pulmanausahakul R, Ubol S. Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness. Microbiol Immunol. 2009;53:442–450. [PubMed] [Google Scholar]
  33. King CA, Anderson R, Marshall JS. Dengue virus selectively induces human mast cell chemokine production. J Virol. 2002;76:8408–8419. [PMC free article] [PubMed] [Google Scholar]
  34. Kurane I, Matsutani T, Suzuki R, Takasaki T, Kalayanarooj S, Green S, Rothman AL, Ennis FA. T-cell responses to dengue virus in humans. Trop Med Health. 2011;39:45–51. [PMC free article] [PubMed] [Google Scholar]
  35. Kurosu T, Chaichana P, Yamate M, Anantapreecha S, Ikuta K. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun. 2007;362:1051–1056. [PubMed] [Google Scholar]
  36. Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, Vaughn DW, Nisalak A, Ennis FA, Rothman AL. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis. 2002;186:1165–1168. [PubMed] [Google Scholar]
  37. Lin CF, Chiu SC, Hsiao YL, Wan SW, Lei HY, Shiau AL, Liu HS, Yeh TM, Chen SH, Liu CC, Lin YS. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J Immunol. 2005;174:395–403. [PubMed] [Google Scholar]
  38. Liu JY, Liu Y, Nie KX, Du SY, Pang XJ, Wang PH, Cheng G. Flavivirus acquisition by mosquitoes requires the secretion of nonstructural protein 1 from infected hosts. Nature Microbiology. 2016;1:16087. [PMC free article] [PubMed] [Google Scholar]
  39. Luo YY, Feng JJ, Zhou JM, Yu ZZ, Fang DY, Yan HJ, Zeng GC, Jiang LF. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC Microbiol. 2013;13:194. [PMC free article] [PubMed] [Google Scholar]
  40. Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, Ogg GS. Cellular and cytokine correlates of severe dengue infection. PLoS One. 2012;7:e50387. [PMC free article] [PubMed] [Google Scholar]
  41. Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, Eckels KH, Putnak R, Kanesa-thasan N, Scherer JM, Statler J, Asher LV, Thomas SJ, Vaughn DW. Evaluation of dengue virus strains for human challenge studies. Vaccine. 2014;32:1488–1494. [PubMed] [Google Scholar]
  42. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM, Ward AM, Gubler DJ, Harris E, Garcia-Blanco MA, Ooi EE. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science. 2015;350:217–221. [PMC free article] [PubMed] [Google Scholar]
  43. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22:564–581. [PMC free article] [PubMed] [Google Scholar]
  44. Martinez Gomez JM, Ong LC, Lam JH, Binte Aman SA, Libau EA, Lee PX, St John AL, Alonso S. Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage. PLoS Negl Trop Dis. 2016;10:e0004536. [PMC free article] [PubMed] [Google Scholar]
  45. Mathew A, Rothman AL. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev. 2008;225:300–313. [PubMed] [Google Scholar]
  46. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, Grimes JM, Yoksan S, Malasit P, Simmons CP, Mongkolsapaya J, Screaton GR. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011;85:410–421. [PMC free article] [PubMed] [Google Scholar]
  47. Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, Hume DA, Stacey KJ, Young PR. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015;7:304ra142. [PubMed] [Google Scholar]
  48. Moon SL, Anderson JR, Kumagai Y, Wilusz CJ, Akira S, Khromykh AA, Wilusz J. A noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. RNA. 2012;18:2029–2040. [PMC free article] [PubMed] [Google Scholar]
  49. Nielsen DG. The relationship of interacting immunological components in dengue pathogenesis. Virol J. 2009;6:211. [PMC free article] [PubMed] [Google Scholar]
  50. Pijlman GP, Funk A, Kondratieva N, Leung J, Torres S, van der Aa L, Liu WJ, Palmenberg AC, Shi PY, Hall RA, Khromykh AA. A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity. Cell Host Microbe. 2008;4:579–591. [PubMed] [Google Scholar]
  51. Rachman A, Harahap AR, Widhyasih RM. The role of antidengue virus NS-1 and anti-protein disulfide isomerase antibodies on platelet aggregation in secondary dengue infection. Acta Med Indones. 2013;45:44–48. [PubMed] [Google Scholar]
  52. Recker M, Vannice K, Hombach J, Jit M, Simmons CP. Assessing dengue vaccination impact: Model challenges and future directions. Vaccine. 2016;34:4461–4465. [PubMed] [Google Scholar]
  53. Rico-Hesse R, Harrison LM, Nisalak A, Vaughn DW, Kalayanarooj S, Green S, Rothman AL, Ennis FA. Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg. 1998;58:96–101. [PubMed] [Google Scholar]
  54. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, Boshell J, de Mesa MT, Nogueira RM, da Rosa AT. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 1997;230:244–251. [PubMed] [Google Scholar]
  55. Ritchie SA, Pyke AT, Hall-Mendelin S, Day A, Mores CN, Christofferson RC, Gubler DJ, Bennett SN, van den Hurk AF. An explosive epidemic of DENV-3 in Cairns, Australia. PLoS One. 2013;8:e68137. [PMC free article] [PubMed] [Google Scholar]
  56. Roby JA, Pijlman GP, Wilusz J, Khromykh AA. Noncoding subgenomic flavivirus RNA: multiple functions in West Nile virus pathogenesis and modulation of host responses. Viruses. 2014;6:404–427. [PMC free article] [PubMed] [Google Scholar]
  57. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–1567. [PubMed] [Google Scholar]
  58. Sasaki T, Setthapramote C, Kurosu T, Nishimura M, Asai A, Omokoko MD, Pipattanaboon C, Pitaksajjakul P, Limkittikul K, Subchareon A, Chaichana P, Okabayashi T, Hirai I, Leaungwutiwong P, Misaki R, Fujiyama K, Ono K, Okuno Y, Ramasoota P, Ikuta K. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Antiviral Res. 2013;98:423–431. [PubMed] [Google Scholar]
  59. Sato R, Hamada N, Kashiwagi T, Imamura Y, Hara K, Nishimura M, Kamimura T, Takasaki T, Watanabe H, Koga T. Dengue Hemorrhagic Fever in a Japanese Traveler with Preexisting Japanese Encephalitis Virus Antibody. Trop Med Health. 2015;43:85–88. [PMC free article] [PubMed] [Google Scholar]
  60. Schnettler E, Sterken MG, Leung JY, Metz SW, Geertsema C, Goldbach RW, Vlak JM, Kohl A, Khromykh AA, Pijlman GP. Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells. J Virol. 2012;86:13486–13500. [PMC free article] [PubMed] [Google Scholar]
  61. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE., Jr. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol. 2012;86:2665–2675. [PMC free article] [PubMed] [Google Scholar]
  62. Srikiatkhachorn A. Plasma leakage in dengue haemorrhagic fever. Thromb Haemost. 2009;102:1042–1049. [PMC free article] [PubMed] [Google Scholar]
  63. Srikiatkhachorn A, Kelley JF. Endothelial cells in dengue hemorrhagic fever. Antiviral Res. 2014;109:160–170. [PMC free article] [PubMed] [Google Scholar]
  64. Sun DS, King CC, Huang HS, Shih YL, Lee CC, Tsai WJ, Yu CC, Chang HH. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. J Thromb Haemost. 2007;5:2291–2299. [PubMed] [Google Scholar]
  65. Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM. Complement-mediated ‘bystander’ damage initiates host NLRP3 inflammasome activation. J Cell Sci. 2016;129:1928–1939. [PMC free article] [PubMed] [Google Scholar]
  66. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77:7539–7544. [PMC free article] [PubMed] [Google Scholar]
  67. Ubol S, Chareonsirisuthigul T, Kasisith J, Klungthong C. Clinical isolates of dengue virus with distinctive susceptibility to nitric oxide radical induce differential gene responses in THP-1 cells. Virology. 2008;376:290–296. [PubMed] [Google Scholar]
  68. Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010;17:1829–1835. [PMC free article] [PubMed] [Google Scholar]
  69. Vasilakis N, Shell EJ, Fokam EB, Mason PW, Hanley KA, Estes DM, Weaver SC. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology. 2007;358:402–412. [PMC free article] [PubMed] [Google Scholar]
  70. Wan SW, Lu YT, Huang CH, Lin CF, Anderson R, Liu HS, Yeh TM, Yen YT, Wu-Hsieh BA, Lin YS. Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. PLoS One. 2014;9:e92495. [PMC free article] [PubMed] [Google Scholar]
  71. WHO/TDR. Dengue guidelines for diagnosis, treatment, prevention and control. Geneva: WHO Press; 2009. [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Springer

 

 

Tags: Dengue antigens

Leave a comment

All comments are moderated before being published